RxDoctor Payments Data

Wai-Lam Chan, MD

Family Medicine · San Francisco, CANPI 1891791877

Payments from drug & device makers

$3,035in general payments, 2019–2025

Across 147 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$403
  • Novo Nordisk$401
  • AstraZeneca$264
  • Pfizer$242
  • Boehringer Ingelheim$236
  • Merck$236
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,027100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,035 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$69,693
Medicare patients
150
Services billed
649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin207$249,825
RybelsusSemaglutide66$135,620
ProliaDenosumab63$105,932
VemlidyTenofovir Alafenamide49$93,149
EliquisApixaban39$61,846
LinzessLinaclotide53$60,587
JanumetSitagliptin Phos/Metformin Hcl36$51,017
XareltoRivaroxaban34$38,573
MounjaroTirzepatide25$31,542
TradjentaLinagliptin37$29,373
OzempicSemaglutide11$27,314
JanuviaSitagliptin Phosphate13$21,905
CreonLipase/Protease/Amylase22$21,511
MyrbetriqMirabegron15$19,743
FarxigaDapagliflozin Propanediol22$18,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$236$279,197244 claims
Novo NordiskRybelsus, Ozempic$401$162,93477 claims
AmgenProlia$210$105,93263 claims
MerckJanumet, Januvia, Janumet Xr, Belsomra$236$97,00775 claims
GileadVemlidy$172$93,14949 claims
AbbVieLinzess, Creon$191$82,09875 claims
PfizerEliquis, Abrysvo, Paxlovid$242$73,50985 claims
Johnson & JohnsonXarelto$403$38,57334 claims
Lilly USA, LLCMounjaro$133$31,54225 claims
Astellas Pharma US IncMyrbetriq$68$19,74315 claims
AstraZenecaFarxiga$264$18,66322 claims
GSKAnoro Ellipta$24$11,33913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →